Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹184.64
8.20 (4.65%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹2.89K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
28.4
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹128.5+43.7%
52W High₹321.95-42.6%
Current Price
₹184.64
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹147.71
Upper Circuit₹221.57
Reference Price
₹184.64
Investment Checklist
Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹206.2
Double Top on 1D (BREAKOUT CONFIRMED) — target ₹228.6
Composite score -39.77 (SELL) with 49.6% confidence
10/20 Bearish Cross detected 3 day(s) ago
EMA(50) Crossover: Price crossed above EMA(50): Fresh bullish momentum signal.
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
50%
Trend
NEUTRAL
NEUTRAL
Mixed MA signals — sideways/transition
EMA20
188.32
EMA50
184.27
EMA200
212.74
Price Action
MIXED
NEUTRAL
Higher Highs2
Higher Lows4
Lower Highs7
Lower Lows5
Support & Resistance Levels
Resistance (Above)
₹194.85
₹200.04
₹211.55
₹224.40
₹228.00
Support (Below)
₹177.58
₹173.80
₹154.47
₹141.10
₹128.50
Volume Analysis
TrendDECREASING
Change-87.00%
Unusual VolumeNo
Recent MA Crossovers
10/20 Bearish Cross
3 days ago
SELL
Stop Loss Levels
Fixed Risk
1% Risk₹182.79
3% Risk₹179.10
5% Risk₹175.41
7% Risk (Custom)
₹171.72Technical Levels
1x ATR (Volatility)₹174.97
2x ATR (Swing)₹165.30
3x ATR (Trend)₹155.63
Immediate Support₹177.58
Moving Averages
EMA 50 (Trend)₹184.27
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹682.3 Cr | ₹646.9 Cr | ₹708.1 Cr | ₹719.8 Cr |
| Net Profit | ₹4.6 Cr | ₹43.1 Cr | ₹23.4 Cr | ₹-13 Cr |
| EPS | ₹0.30 | — | ₹1.49 | ₹-0.83 |
| Operating Profit | ₹147.8 Cr | ₹141 Cr | ₹162.8 Cr | ₹119.8 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 12 Sept 2019 | Dividend - Rs 0.20 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for DCAL
View AllNEWS
negative
Business Standard - Markets 22d ago
Suraj Ltd leads losers in 'B' group
SMS Pharmaceuticals Ltd, RSD Finance Ltd, Grand Oak Canyons Distillery Ltd and Dishman Carbogen Amcis Ltd are among the other losers in the BSE's 'B' group today, 22 May 2026.
BSEDCALGRANDOAKLTFRSDFINSMSPHARMASURAJLTDCapital GoodsFinancial Services
NEWS
positive
Business Standard - Markets 24d ago
Dishman Carbogen Amcis consolidated net profit declines 49.55% in the March 2026 quarter
Sales rise 18.85% to Rs 851.40 crore
DCALHealthcare